Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

SOUTH SAN FRANCISCO, Calif., and BOSTON  – Frontier Medicines Corporation, a precision medicine company advancing transformative drugs against historically undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:00 a.m. PT.

The virtual presentation will be available to registered attendees of the J.P. Morgan Healthcare Conference through the conference portal.

About Frontier Medicines

Frontier Medicines is a precision medicine company that has pioneered the Frontier™ Platform, a powerful drug discovery engine designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to develop potentially groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing a deep pipeline of wholly-owned precision medicines against the most important drivers of cancer. The company’s lead program directly inhibits both the active and inactive forms of KRASG12C, potentially overcoming non-response and resistance seen with prior generation KRASG12C inhibitors. For more information on how Frontier is boldly advancing science to defeat disease, visit and follow us on LinkedIn and Twitter.